Efficacy of 18 F ‐Fluoro‐2‐Deoxyglucose Positron Emission Tomography as a Predictor of Treatment Response to Neoadjuvant S‐1 + Oxaliplatin Chemotherapy for Gastric Cancer
Cancer Reports · 2025
DOI: 10.1002/cnr2.70190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Naoki Urakawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Positron-Emission Tomography. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant chemotherapy is widely recognized as the established treatment for advanced gastric cancer. However, predicting its efficacy before surgery remains challenging.
Aim
The present study aimed to evaluate the effectiveness of 18F‐fluoro‐2‐deoxyglucose positron emission tomography (FDG‐PET) as a predictor of treatment response to the S‐1+Oxaliplatin regimen (SOX). Methods and Results Thirty patients who underwent gastrectomy following neoadjuvant SOX between January 2021 and July 2023 were included. Patients underwent FDG‐PET pre‐ and postsurgery. The maximum standardized uptake value (SUVmax) from FDG‐PET was examined in relation to histological tumor response and prognosis. SUVmax decreased significantly after chemotherapy in all patients ( p < 0.001), especially in those with Grade 1a, 2, and 3 tumors ( p < 0.05). SUV reduction increased stepwise with the histological response grade. Optimal cut‐off values for the percentage decrease in SUVmax (ΔSUVmax) predictive of histologic efficacy were identified as 53% (area under curve 0.855, p = 0.0018) for Grade 1b or higher and 75% (area under curve 0.806, p = 0.0044) for Grade 2 or higher. Patients with ΔSUVmax > 50% had improved recurrence‐free survival ( p = 0.027).
Conclusion
FDG‐PET may be useful as a predictor of treatment response in neoadjuvant SOX therapy for gastric cancer. The determination of the optimal ΔSUVmax value may enhance the precision of histological tumor response prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Shingo Kanaji, Hironobu Goto
Zitieren
APA
Urakawa, N., Kanaji, S., Sawada, R., Koterazawa, Y., Ikeda, T., Harada, H., Goto, H., Hasegawa, H., Yamashita, K., Matsuda, T., & Kakeji, Y. (2025). Efficacy of 18 F ‐Fluoro‐2‐Deoxyglucose Positron Emission Tomography as a Predictor of Treatment Response to Neoadjuvant S‐1 + Oxaliplatin Chemotherapy for Gastric Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70190
Vancouver
Urakawa N, Kanaji S, Sawada R, Koterazawa Y, Ikeda T, Harada H, et al. Efficacy of 18 F ‐Fluoro‐2‐Deoxyglucose Positron Emission Tomography as a Predictor of Treatment Response to Neoadjuvant S‐1 + Oxaliplatin Chemotherapy for Gastric Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70190
BibTeX
@article{Urakawa2025,
author = {Urakawa, Naoki and Kanaji, Shingo and Sawada, Ryuichiro and Koterazawa, Yasufumi and Ikeda, Taro and Harada, Hitoshi and Goto, Hironobu and Hasegawa, Hiroshi and Yamashita, Kimihiro and Matsuda, Takeru and Kakeji, Yoshihiro},
title = {Efficacy of 18 F ‐Fluoro‐2‐Deoxyglucose Positron Emission Tomography as a Predictor of Treatment Response to Neoadjuvant S‐1 + Oxaliplatin Chemotherapy for Gastric Cancer},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70190}
}
EUVIMED